| Project/Area Number |
22659185
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
NAKASHIMA Ran 京都大学医学部附属病院, 免疫・膠原病内科, 医員
HOSONO Yuji 京都大学, 大学院・医学研究科内科学講座臨床免疫学, 大学院生
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,230,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥1,800,000 (Direct Cost: ¥1,800,000)
|
|---|
| Keywords | IFIH1 / MDA5 / CADM-140 / 自己抗体 / 皮膚筋炎 / 間質性肺炎 / サイトカイン / HLA / ADM |
|---|
| Research Abstract |
A disease-specific autoantibody, termed anti-CADM-140 antibody, is found in patients with amyopathic dermatomyositis accompanied with lethal acute interstitial pneumonia. We identified that the target autoantigen recognized by anti-CADM-140 antibody was IFIH1/MDA5, a viral RNA receptor in cytoplasm. The patients with anti-CADM-140 antibody revealed higher level of serum ferritin as well as IL-6, IL-10, IL-18 and M-CSF than antibody-negative dermatomyositis patients, suggesting the macrophage activating state. The intensive immunosuppressive therapy(high-dose glucocorticoids, cyclosporine and intravenous cyclophosphamide pulse) appeared to improve a life prognosis of antibody-positive patients when compared with the conventional step-up therapy.
|
